Abstract:ABSTRACT New and improved drugs are required for the treatment and ultimate eradication of malaria. The efficacy of front-line therapies is now threatened by emerging drug resistance; thus, new tools to support the development of drugs with a lower propensity for resistance are needed. Here, we describe the development of a RESistance Mapping And Profiling (ResMAP) platform for the identification of resistance-conferring mutations in Plasmodium drug targets. Proof-of-concept studies focused on interrogating the antimalarial drug target, Plasmodium falciparum lysyl tRNA synthetase ( Pf KRS). Saturation mutagenesis was used to construct a plasmid library encoding all conceivable mutations within a 20-residue span at the base of the Pf KRS ATP-binding pocket. The superior transfection efficiency of Plasmodium knowlesi was exploited to generate a high coverage parasite library expressing Pf KRS bearing all possible amino acid changes within this region of the enzyme. The selection of the library with Pf KRS inhibitors, cladosporin and DDD01510706, successfully identified multiple resistance-conferring substitutions. Genetic validation of a subset of these mutations confirmed their direct role in resistance, with computational modeling used to dissect the structural basis of resistance. The application of ResMAP to inform the development of resistance-resilient antimalarials of the future is discussed. IMPORTANCE An increase in treatment failures for malaria highlights an urgent need for new tools to understand and minimize the spread of drug resistance. We describe the development of a RESistance Mapping And Profiling (ResMAP) platform for the identification of resistance-conferring mutations in Plasmodium spp, the causative agent of malaria. Saturation mutagenesis was used to generate a mutation library containing all conceivable mutations for a region of the antimalarial-binding site of a promising drug target, Plasmodium falciparum lysyl tRNA synthetase ( Pf KRS). Screening of this high-coverage library with characterized Pf KRS inhibitors revealed multiple resistance-conferring substitutions including several clinically relevant mutations. Genetic validation of these mutations confirmed resistance of up to 100-fold and computational modeling dissected their role in drug resistance. We discuss potential applications of this data including the potential to design compounds that can bypass the most serious resistance mutations and future resistance surveillance.

MicroRNA Guided In Silico Drug Repositioning for Malaria

Structure-Based Virtual Screening, Insilico Docking, ADME Prediction, and Molecular Dynamics Studies for Identification of Potential NMT Inhibitors Against Malaria

Unveiling Potential Repurposed Drug Candidates for Plasmodium falciparum through In Silico Evaluation: A Synergy of Structure-based Approaches, Structure Prediction, and Molecular Dynamics Simulations

Ex vivo and In vitro antiplasmodial activities of approved drugs predicted to have antimalarial activities using chemogenomics and drug repositioning approach

Computational approach for decoding malaria drug targets from single-cell transcriptomics and finding potential drug molecule

Deep Learning-driven research for drug discovery: Tackling Malaria

In silico drug repositioning based on drug-miRNA associations

Innovative Multistage ML-QSAR Models for Malaria: From Data to Discovery

Repurposing FDA‐approved drugs to target malaria through inhibition of dihydrofolate reductase in the folate biosynthesis pathway: A prospective approach

Identification of Malaria-Selective Proteasome β5 Inhibitors Through Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulation

Approved drugs successfully repurposed against Leishmania based on machine learning predictions

Protein target similarity is positive predictor of in vitro antipathogenic activity: a drug repurposing strategy for Plasmodium falciparum

Antimalarial Drug Combination Predictions Using the Machine Learning Synergy Predictor (MLSyPred©) tool

Exploring the recent pioneering developments of small molecules in antimalarial drug armamentarium: A chemistry prospective appraisal

ResMAP—a saturation mutagenesis platform enabling parallel profiling of target-specific resistance-conferring mutations in Plasmodium

Functional Phenotyping of MMV Pandemic Response Box Identifies Stage-specific inhibitors Against Blood stage Plasmodium

Exploring Genetic Silencing: RNAi and CRISPR-Cas Potential Against Drug Resistance in Malaria

Antimalarial Drug Predictions Using Molecular Descriptors and Machine Learning against Plasmodium Falciparum

Structural Exploration of the PfBLM Helicase-ATP Binding Domain and Its Implications in the Quest for Antimalarial Therapies

Identification of novel Plasmodium falciparum dihydroorotate dehydrogenase inhibitors for malaria using in silico studies